A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies
Eleftheria Kalogera(Palmetto General Hospital), Matthew S. Block(Mayo Clinic in Arizona), Carrie Langstraat(Mayo Clinic), Carrie Strand(Mayo Clinic), Sarah A. Buhrow(Mayo Clinic), Rachel A. Kudgus(Mayo Clinic), Andrea E. Wahner Hendrickson(Mayo Clinic in Arizona), Joel M. Reid(Children's Hospital of Philadelphia), Yiyi Yan, Laura Becher(Mayo Clinic), Gretchen Glaser(Mayo Clinic), Wendy K. Nevala(Mayo Clinic), Heidi D. Finnes(Mayo Clinic), Aminah Jatoi(Mayo Clinic in Arizona), Jill M. Schimke(Mayo Clinic), Lisa A. Kottschade(Mayo Clinic in Arizona), Amanika Kumar(Mayo Clinic), Megan E. Grudem(Mayo Clinic), Vera J. Suman(Mayo Clinic), Svetomir N. Markovic(Mayo Clinic), Carolyn M. Klampe(Mayo Clinic), Liyi Geng(Mayo Clinic), S. John Weroha(University of Kansas), Robert R. McWilliams(Mayo Clinic)
Cited by 15
Related Papers
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer
|Nature Genetics|2009|724
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33
|Nature Genetics|2010|614